Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Welgene Biotech Co's Enterprise Value is NT$370.8 Mil.
Welgene Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-6.8 Mil. Therefore, Welgene Biotech Co's EV-to-FCF for today is -54.76.
The historical rank and industry rank for Welgene Biotech Co's EV-to-FCF or its related term are showing as below:
ROCO:6661'
s EV-to-FCF Range Over the Past 10 Years
Min: -841.39 Med: 7.32 Max: 292.19
Current: -56.31
During the past 12 years, the highest EV-to-FCF of Welgene Biotech Co was 292.19. The lowest was -841.39. And the median was 7.32.
ROCO:6661's EV-to-FCF is ranked worse than 100% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.22
vs ROCO:6661: -56.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Welgene Biotech Co (ROCO:6661) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Welgene Biotech Co's PE Ratio (TTM) for today is calculated as:
Welgene Biotech Co's share price for today is NT$17.55.
Welgene Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Welgene Biotech Co EV-to-FCF Related Terms
Welgene Biotech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Welgene Biotech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Welgene Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Welgene Biotech Co EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Welgene Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Welgene Biotech Co's EV-to-FCF falls into.
Welgene Biotech Co's current Enterprise Value is NT$370.8 Mil.
Welgene Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-6.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Welgene Biotech Co (ROCO:6661) has a EV-to-FCF of -54.76 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Welgene Biotech Co and its competitors. According to the industry distribution chart, Welgene Biotech Co ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry.
Is Welgene Biotech Co's EV-to-FCF too high?
Welgene Biotech Co's current EV-to-FCF is -54.76. Based on the distribution chart, Welgene Biotech Co ranks #999999 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Welgene Biotech Co has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Welgene Biotech Co ranks #999999 out of 99 companies for EV-to-FCF. This places Welgene Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 27.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.22, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Welgene Biotech Co and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Welgene Biotech Co's current EV-to-FCF is -54.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.93, compared to a current price of NT$17.55 — trading 41.4% below its estimated fair value. The current EV-to-FCF is -54.76. Welgene Biotech Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current EV-to-FCF is -54.76 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?
Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued.
The current stock price of NT$17.55 is trading 41.4% below its estimated GF Value™ of NT$29.93.
GuruFocus considers Welgene Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:6661:
EV-to-FCF: -54.76
GF Value™: NT$29.93 vs. price of NT$17.55 (41.4% below fair value)
No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
70GF Score
Get the complete analysis for ROCO:6661
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6661 has been successfully added to your 
